Report Highlights

Sacroiliitis Care in the United States: Market Overview

The US sacroiliitis market spans interventional diagnostics, implantable sacroiliac joint fusion devices, image-guided procedures and biologic therapies for inflammatory axial spondyloarthritis. This analysis values it at USD 1.42 billion in 2024, with device revenue concentrated among a few manufacturers. Private companies have led product design and commercialization, most visibly SI-BONE, which built the minimally invasive fusion category around its iFuse implant family. Government shapes the commercial ceiling, since CMS fee schedules and Medicare coverage rules determine what providers are paid.

Government has been the dominant force in access and pricing, not in innovation. FDA 510(k) clearance and premarket approval decide which implants can be marketed, while Medicare Administrative Contractor local coverage determinations set the conditions that turned fusion into a recognized procedure category. Private R&D drives clinical evidence and product iteration. Biologic demand for inflammatory sacroiliitis follows Medicare Part B and Part D formulary decisions, leaving manufacturers exposed to federal price negotiation.

Policy-Driven Growth in US Sacroiliitis Care

Three federal mechanisms drive demand. First, Section 11403 of the Inflation Reduction Act of 2022 (Public Law 117-169) grants qualifying Part B biosimilars a temporary add-on payment of 8 percent of the reference product's average sales price. This improves the economics of biosimilar biologics used for axial spondyloarthritis, lowering acquisition cost and widening the treated population for inflammatory sacroiliitis.

Second, Medicare Administrative Contractor local coverage determinations on sacroiliac joint fusion, administered by contractors such as Palmetto GBA and Noridian JE, require documented failure of conservative therapy and a positive diagnostic injection before fusion is reimbursed. This creates a mandatory diagnostic funnel that converts image-guided injections into the qualifying step toward surgical fusion volume. Third, CPT code 27279, describing percutaneous image-guided sacroiliac joint arthrodesis with implant placement, gives providers a distinct billing code. CMS annual Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules set its payment, so stable reimbursement converts clinical adoption into revenue.

Regulatory Barriers and Compliance Costs in US Sacroiliitis Care

FDA's Center for Devices and Radiological Health administers premarket review. Most SI fusion implants reach market through 510(k) clearance, carrying a MDUFA V performance goal of 90 FDA days, while novel designs require premarket approval with a 180-day review goal. Manufacturers must also comply with the Quality Management System Regulation at 21 CFR Part 820, which aligns with ISO 13485 from 2 February 2026, adding documentation and audit costs for smaller firms.

Medicare coverage imposes the largest practical delay. Local coverage determinations require documented conservative care and diagnostic response before reimbursement, and criteria vary by MAC jurisdiction, forcing multi-regional evidence files. Biologics face prior authorization and step therapy under Part D plans. The Anti-Kickback Statute (42 U.S.C. 1320a-7b(b)) restricts manufacturer support programs, requiring compliance review that consumes substantial legal resources.

Policy-Created Opportunities in US Sacroiliitis Care

The Transitional Coverage for Emerging Technologies pathway, finalized by CMS in August 2024, provides provisional Medicare payment for technologies with FDA Breakthrough Device designation, under the designation created by Section 515B of the Federal Food, Drug, and Cosmetic Act. Companies developing image-guided SI fusion or novel sensing technologies can use this route to secure coverage while long-term evidence accumulates, accelerating commercial entry.

Site-of-service migration creates a second opportunity. CMS has progressively expanded the Ambulatory Surgical Center Covered Procedures List, and ASC facility payments for minimally invasive procedures are lower than hospital outpatient payments. Device makers that certify ASC-compatible instrumentation and sterile kits capture this shift, while biosimilar uptake under the Inflation Reduction Act creates demand for injection and monitoring services.

Market at a Glance

Leading Market Participants

• SI-BONE
• Medtronic
• Globus Medical
• Stryker
• DePuy Synthes
• Zimmer Biomet
• AbbVie
• Amgen
• Novartis
• UCB

Regulatory and Policy Environment for Sacroiliitis in the U.S.

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), which governs device classification, premarket clearance and quality obligations enforced by FDA's Center for Devices and Radiological Health. Coverage and payment sit under Title XVIII of the Social Security Act, administered by CMS and its MACs. The Inflation Reduction Act of 2022 (Public Law 117-169) and the Biologics Price Competition and Innovation Act of 2009 govern biologic pricing and biosimilar approval.

Key compliance requirements include Medical Device Reporting under 21 CFR Part 803, Open Payments reporting under Section 6002 of the Affordable Care Act, and Anti-Kickback Statute compliance for sales arrangements. Upcoming changes include QMSR enforcement from 2 February 2026, Enbrel negotiated prices effective 1 January 2026, and Part B drug negotiation from the 2028 selection cycle. Compared with Canada's Medical Devices Regulations (SOR/98-282) and the EU's Medical Device Regulation (EU) 2017/745, the US framework is fragmented across FDA, CMS and multiple MACs.

Long-Term Policy Outlook for US Sacroiliitis Care

From 2028, Medicare Part B drugs become eligible for Inflation Reduction Act price negotiation, placing clinic-administered biologics for axial spondyloarthritis under federal maximum fair prices. Payers will shift inflammatory and mechanical sacroiliitis spending toward procedural alternatives, and device makers gain the most from this rebalancing.

CMS's Transitional Coverage for Emerging Technologies pathway and continued ASC list expansion will determine whether image-guided and minimally invasive fusion dominate procedure volume by 2032. Growing Medicare beneficiary cohorts, documented diagnostic criteria and lower facility costs will push the market toward USD 2.31 billion, with outpatient ASCs capturing the largest share of incremental volume.